Project Grant R44HL129543

This Project Grant award of $2,461,670.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the development of ErythroMer (EM), a dried, bio-inspired artificial red blood cell substitute, by Kalocyte Inc., a biotech startup. The project aims to optimize the lyophilization and reconstitution of EM to improve its oxygen binding and release properties, as well as evaluate its efficacy, pharmacokinetics, dosing, and compatibility with...

This three-year, $1.977 million Project Grant from the Department of the Army Medical Command will support Cytosorbents Medical Inc.'s demonstration of the safety and efficacy of its field-ready blood group antibody (BGA) adsorber in a porcine universal transfusion model. The Military Medical Research and Development program (CFDA 12.420) aims to transform military and public health care through innovative biomedical research solutions for battlefield medicine. Under this award, Cytosorbents...

This $8,042,749 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) is funding research at The Ohio State University to enhance the safety and efficacy of low-titer Group O whole blood. The research involves determining optimal concentrations of hemopexin, haptoglobin, and transferrin to neutralize hemolytic byproducts during ex vivo storage of whole blood units. The project includes testing this protein...

This Project Grant award of $507,517.00 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) aims to develop novel, synthetic therapies for stabilizing trauma victims in the critical "golden hour" after injury. The primary objectives are to engineer low-volume resuscitants that provide fluid resuscitation while preserving the patient's coagulation...

The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. was awarded a $277,569 cooperative agreement from the Department of Defense Uniformed Services University of the Health Sciences to develop and test acetazolamide as a treatment to extend the golden hour for trauma patients. Under the Uniformed Services University Medical Research Projects program (CFDA 12.750), the Foundation will conduct research from November 1, 2022 to April 30, 2025 to evaluate whether...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $295,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Hematherix LLC, a woman-owned small business in California. The award supports the development of SuperFVa, an engineered variant of activated coagulation cofactor Factor V, as a targeted therapy to prevent and correct acute traumatic coagulopathy (ATC). ATC is characterized by diminished levels of key clotting factors, leading to...

This $181,772 project grant from the National Heart, Lung and Blood Institute will support research into coagulopathy in sepsis patients. The grantee, Beth Israel Deaconess Medical Center, will conduct an ancillary study using viscoelastic monitoring to examine the effects of randomly assigned fluid resuscitation strategies on coagulation parameters in sepsis patients. Specifically, the study aims to: 1) analyze how liberal versus restrictive fluid administration impacts coagulation measurements...

This $3,055,695 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports the University of Utah's research on developing GJA1-20K as a novel treatment for hemorrhagic shock. The goal is to minimize mitochondrial injury and mitigate ischemia-reperfusion injury. This 4-year project, running from April 2024 through April 2028, will advance innovative biomedical research with potential to improve health outcomes for...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $889,188 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Children's Hospital Corporation, doing business as Boston Children's Hospital. The grant supports the development of a novel intravenous oxygen (IVO2) therapy using pH-responsive polymeric microbubbles to improve oxygenation and survival rates for cardiac arrest patients, particularly in cases of asphyxia-induced cardiac arrest. The...

The Department of the Army Medical Command awarded a $1,093,692.71 Project Grant to HMH Hospitals Corporation, doing business as Hackensack University Medical Center, to support a randomized clinical study of convalescent plasma from recovered COVID-19 donors collected through plasmapheresis as treatment for early COVID-19 infection. The study aims to evaluate the safety and efficacy of convalescent plasma as a treatment option for COVID-19 under the Military Medical Research and Development...